Compare HDSN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDSN | SLN |
|---|---|---|
| Founded | 1991 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 409.2M | 318.4M |
| IPO Year | 1994 | N/A |
| Metric | HDSN | SLN |
|---|---|---|
| Price | $7.31 | $6.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.50 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 524.0K | 280.4K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $236,847,000.00 | $25,830,000.00 |
| Revenue This Year | $2.65 | N/A |
| Revenue Next Year | $3.69 | N/A |
| P/E Ratio | $14.55 | ★ N/A |
| Revenue Growth | N/A | ★ 40.39 |
| 52 Week Low | $5.11 | $1.97 |
| 52 Week High | $10.52 | $8.88 |
| Indicator | HDSN | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 56.90 |
| Support Level | $6.53 | $5.98 |
| Resistance Level | $7.74 | $6.88 |
| Average True Range (ATR) | 0.27 | 0.52 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 63.64 | 71.63 |
Hudson Technologies Inc is an American industrial products manufacturer. It develops products which are mainly used in commercial air conditioning, industrial processing, and refrigeration systems. The company products include refrigerant and industrial gases, refrigerant management services and RefrigerantSide services, which consist of system decontamination. These are performed at customer's site using its Zugibeast system, which is a fast and portable system and allows the R-Side services team to accelerate critical services while saving customers time, money and aggravation. The company also owns a web-based real-time monitoring service which is used in the facility's refrigeration systems and other energy systems.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.